Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Date

Click to order products descending

Display 45 Products per page

Fovista
Read More
Fovista (pegpleranib; Ophthotech/Novartis) is a PEGylated aptamer targeting platelet-derived growth factor (PDGF). The drug is designed to be used in combination with a vascular endothelial growth factor (VEGF) inhibitor.
April 7, 2016
Find out more
Macugen
Read More
Macugen (pegaptanib; Valeant/Pfizer) is a PEGylated oligonucleotide aptamer which binds selectively

to vascular endothelial growth factor (VEGF)-165, an isoform of VEGF found to induce angiogenesis

and increase vascular permeability (Natarajan, 2013).
April 7, 2016
Find out more
blisibimod
Read More
Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
April 5, 2016
Find out more
Visudyne
Read More
Visudyne (verteporfin; Valeant/Novartis) is a benzoporphyrin derivative photosensitizer developed for

use in photodynamic therapy.
April 4, 2016
Find out more
Herceptin
Read More
Herceptin is a humanized MAb targeting the HER2 receptor, a member of the human epidermal

growth factor receptor family.
March 22, 2016
Find out more
Reasanz
Read More
Reasanz (serelaxin; Novartis) has not yet obtained approval in the US, Japan, or EU for the treatment

of acute decompensated heart failure (ADHF), despite its fast track and breakthrough therapy

designations from the US Food and Drug Administration (FDA).
March 16, 2016
Find out more
Ularitide
Read More
Ularitide’s (Cardiorentis) favorable results in its pivotal Phase III trial could be a key driver of uptake,

especially as Natrecor (nesiritide; Johnson & Johnson), its major marketed competitor, failed to show

added clinical value and benefit on survival.
March 16, 2016
Find out more
Bax 817
Read More
BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…
March 14, 2016
Find out more
CSL627
Read More
CSL627 is a single-chain rfVIII product in development for hemophilia A. Endogenously produced fVIII consists of a light chain and a heavy chain fused via a metal ion bridge.
March 14, 2016
Find out more
Cometriq
Read More
Cometriq is an orally available small molecule inhibitor currently being developed by Exelixis as

second-line therapy for patients with relapsed or metastatic RCC.
February 5, 2016
Find out more
AGS-003
Read More
AGS-003 (Argos Therapeutics/Kyowa Hakko Kirin) is a cancer vaccine in development for the first-line treatment of metastatic renal cell cancer (RCC) in combination with Sutent (sunitinib; Pfizer).
February 5, 2016
Find out more
Entinostat
Read More
Entinostat is a class I selective histone deacetylase (HDAC) inhibitor. HDACs influence the expression of genes involved in both the initiation of cancer
February 5, 2016
Find out more
Taselisib
Read More
Taselisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in
tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Find out more
Alpelisib
Read More
Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Find out more
Ixempra
Read More
Ixempra (ixabepilone; R-Pharm/Otsuka) is a lactam analog of epothilone B that binds to microtubules via tubulin.
February 4, 2016
Find out more
Ibrance
Read More
Ibrance (palbociclib; Pfizer) is a small-molecule inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). When associated with cyclin-D proteins, CDK4/6 are able to phosphorylate and inactivate.
February 4, 2016
Find out more
Faslodex
Read More
Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER).
February 2, 2016
Find out more
MF-59 adjuvanted QIV
Read More
CSL’s MF-59 adjuvanted QIV is a subunit, surface antigen-containing seasonal QIV adjuvanted withMF59. It contains antigens from two A strains and two B strains specified by the World HealthOrganization seasonally for seasonal influenza vaccination.
February 2, 2016
Find out more
VLP QIV
Read More
Novavax’s virus-like particle (VLP) quadrivalent influenza vaccine (QIV), currently in Phase II

development, has the potential for significant market success if it is able to demonstrate superior

safety or efficacy data in Phase III studies.
February 2, 2016
Find out more
Ampyra
Read More
Ampyra is a potassium channel blocker, marketed by Acorda Therapeutics and Biogen, which is

approved to improve walking ability in multiple sclerosis patients. Although Ampyra’s active molecule

fampridine (4-aminopyridine) is readily available, by using Elan’s Intestinal Protective Drug Absorption

System, Acorda has developed a sustained-released oral tablet formulation allowing twice-daily

dosing.
January 26, 2016
Find out more
Zaltrap
Read More
Zaltrap is a human recombinant fusion protein comprising segments of the human VEGFRs 1 and 2
and the Fc portion of the human immunoglobulin G1 (Tang et al., 2008).
January 19, 2016
Find out more
Peretinoin
Read More
Peretinoin (Kowa/Chugai Pharmaceutical) is a synthetic acyclic retinoid inhibitor of transforming growth factor alpha (TGF-alpha) and platelet-derived growth factor receptor (PDGFR). TGF-alpha induces epithelial development, and is closely involved in hepatocarcinogenesis.
December 31, 2015
Find out more
Tivantinib
Read More
Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.
December 31, 2015
Find out more
F/TAF
Read More
F/TAF (emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a fixed-dose combination of two of Gilead’s nucleoside reverse transcriptase inhibitors, Emtriva (emtricitabine) and GS-7340 (TAF).
December 11, 2015
Find out more
D/C/F/TAF
Read More
D/C/F/TAF is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), the two nucleoside reverse transcriptase inhibitors…
December 11, 2015
Find out more
Tybost
Read More
Tybost (cobicistat; Gilead) is a boosting agent to be used in combination with protease inhibitors (PIs) as part of treatment regimens for HIV-1 infection.
December 11, 2015
Find out more
Recentin
Read More
Recentin (cediranib; AstraZeneca) is a small molecule inhibitor of all three vascular endothelial growth factor receptor (VEGFR-1, -2, -3) tyrosine kinases.
October 30, 2015
Find out more
Vigil
Read More
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
October 30, 2015
Find out more
ChimeriVax-Dengue
Read More
ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs.
October 28, 2015
Find out more
ProstAtak
Read More
ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine.
September 24, 2015
Find out more
Ganetespib
Read More
Ganetespib, under development by Synta, is a small molecule inhibitor of HSP90. HSP90 is a chaperone protein required to drive growth, proliferation, and cell survival in tumor tissue.
September 17, 2015
Find out more
Venetoclax
Read More
Venetoclax (AbbVie/Roche) is a novel B-cell lymphoma-2 (BCL-2) inhibitor currently being developed

for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL).
September 11, 2015
Find out more
omadacycline
Read More
Omadacycline (Paratek Pharmaceuticals) is the first agent of the aminomethycyclines class of antibiotics. The drug, which is a semisynthetic derivative of the tetracycline minocycline.
June 19, 2015
Find out more
Invanz
Read More
Invanz (ertapenem; Merck & Co) is a carbapenem antibacterial agent that inhibits bacterial cell wall synthesis through binding to penicillin-binding proteins. The drug inhibits the crosslinking of…
June 19, 2015
Find out more
Factive
Read More
Factive (gemifloxacin mesylate; Vansen Pharma) is an oral synthetic broad-spectrum antibacterial agent related to the fluoroquinolone class of antibiotics.
June 19, 2015
Find out more
Zyvox
Read More
Pfizer developed Zyvox (linezolid) as the first oxazolidinone antimicrobial agent. The drug gained its first regulatory approval for the treatment of complicated skin and skin structure infections (cSSSI) in the US market in 2000.
June 19, 2015
Find out more
Zeftera
Read More
Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin.
June 19, 2015
Find out more
Beraprost 314d
Read More
Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…
June 19, 2015
Find out more
Spectracef
Read More
Spectracef (cefditoren pivoxil; Vansen Pharma) is an oral semisynthetic, broad-spectrum, third-generation cephalosporin. After oral administration, the pro-drug, cefditoren pivoxil, is converted to the active drug, cefditoren, through esterase hydrolysis.
June 19, 2015
Find out more
solithromycin
Read More
Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP.
June 19, 2015
Find out more
Tygacil
Read More
Tygacil (tigecycline; Pfizer) is the first of the glycylcycline class of antimicrobial agents. It targets and binds to the 30S subunit of the bacterial ribosomes.
June 19, 2015
Find out more
Ketek
Read More
Ketek (telithromycin; Sanofi) is an oral semisynthetic antibacterial agent of the ketolide class. The drug, which is the first ketolide to gain regulatory approval for the treatment of community-acquired pneumonia, is structurally related to the macrolide class of antibiotics.
June 19, 2015
Find out more
Tenofovir alafenamide fumarate
Read More
TAF is a prodrug form of tenofovir, the active ingredient in Viread. Tenofovir mimics the natural
substrate of reverse transcriptase and is incorporated into nascent viral DNA strands during
replication. Once incorporated, tenofovir acts as a chain terminator and prevents further replication of
the viral genome (FDA.gov, 2013).
May 14, 2015
Find out more
Delzicol/Asacol HD
Read More
This product profile relates to the mesalamine franchise that covers Delzicol (mesalamine; Actavis), Asacol (mesalamine; Zeria/Kyowa Hakko Kirin), and Asacol HD (mesalamine; Actavis/Zeria)…
May 1, 2015
Find out more
Actemra
Read More
Actemra (tocilizumab; Roche/Chugai), known as RoActemra in Europe, is a first-in-class humanized interleukin-6 receptor monoclonal antibody.
March 24, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *